BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada

Pharmaceutical Investing

BioDelivery Sciences International (NASDAQ:BDSI) and Purdue Pharma announced today that BELBUCA® (buprenorphine) buccal film is now commercially available in Canada. As quoted in the press release: “It is important for us to work with an organization that has a strong commitment to pain management in Canada, such as Purdue Pharma (Canada), and we are very …

BioDelivery Sciences International (NASDAQ:BDSI) and Purdue Pharma announced today that BELBUCA® (buprenorphine) buccal film is now commercially available in Canada.
As quoted in the press release:

“It is important for us to work with an organization that has a strong commitment to pain management in Canada, such as Purdue Pharma (Canada), and we are very pleased that BELBUCA is now available to Canadian patients managing chronic pain,” said Scott Plesha, President of BioDelivery Sciences

Click here to read the full press release.

biodelivery sciences canada chronic pain pain patients us Pharmaceutical Investing